ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients

ClinicalTrials.gov ID: NCT03961009

Public ClinicalTrials.gov record NCT03961009. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open-label, Prospective, Multicenter Study to Assess Efficacy, Safety and Pharmacokinetics of Kedrion Intravenous Immunoglobulin (IVIg) 10% in Primary Immunodeficiency Disease (PID) Patients

Study identification

NCT ID
NCT03961009
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Kedrion S.p.A.
Industry
Enrollment
47 participants

Conditions and interventions

Interventions

  • Kedrion IVIG 10% Biological

Biological

Eligibility (public fields only)

Age range
2 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 29, 2019
Primary completion
Dec 20, 2020
Completion
Dec 20, 2020
Last update posted
May 4, 2026

2019 – 2020

United States locations

U.S. sites
11
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
Allergy Associates of the Palm Beaches North Palm Beach Florida 33408
Rush University Medical Center Chicago Illinois 60612
Dr. Henry J. Kanarek - Allergy, Asthma & Immunology Overland Park Kansas 66211
Midwest Immunology Clinic and Infusion Center Plymouth Minnesota 55446
Allergy and Immunology Associates Little Silver New Jersey 07739
University of Buffalo Buffalo New York 14203
Optimed Research Columbus Ohio 43235
Ohio Clinical Research Associates, Inc. Mayfield Heights Ohio 44124
Toledo Institute of Clinical Research Inc Toledo Ohio 43617
Allergy Partners of North Texas Research Dallas Texas 75230
AARA Research Center Dallas Texas 75231

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03961009, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03961009 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →